# Development of siRNA Therapeutics for the Treatment of Liver Diseases siRNA 疗法在肝病治疗中的应用

Anja Holm, Marianne Bengtson Løvendorf and Sakari Kauppinen

## Abstract 摘要

Small interfering RNA (siRNA)-based therapeutics holds the promise to treat a wide range of human diseases that are currently incurable using conventional therapies. Most siRNA therapeutic efforts to date have focused on the treatment of liver diseases due to major breakthroughs in the development of efficient strategies for delivering siRNA drugs to the liver. Indeed, the development of lipid nanoparticle-formulated and GalNAc-conjugated siRNA therapeutics has resulted in recent FDA approvals of the first siRNA-based drugs, patisiran for the treatment of hereditary transthyretin amyloidosis and givosiran for the treatment of acute hepatic porphyria, respectively. Here, we describe the current strategies for delivering siRNA drugs to the liver and summarize recent advances in clinical development of siRNA therapeutics for the treatment of liver diseases.

<span style=color:blue>基于小干扰RNA（siRNA）的治疗方法有望治疗许多目前无法通过传统疗法治愈的人类疾病。目前，大多数siRNA治疗的研究都集中在肝脏疾病上，这是由于在高效输送siRNA药物至肝脏方面取得了重大突破。实际上，脂质纳米粒制剂和GalNAc-缀合siRNA疗法的发展，促使首批siRNA药物获得了FDA批准，即用于治疗遗传性转甲状腺素蛋白淀粉样变性症的patisiran和用于治疗急性肝卟啉病的givosiran。本文描述了当前siRNA药物输送到肝脏的策略，并总结了在肝脏疾病治疗中siRNA疗法临床开发的最新进展。</span>

## 1 Introduction 简介

The discovery of RNA interference (RNAi) and the use of synthetic 21–23 nucleotide (nt) double-stranded RNAs, named siRNAs, to trigger post-transcriptional gene silencing in mammalian cells in a sequence-specific manner have revolutionized functional genomic studies and biomedical research . Furthermore, marked improvements in the design, chemical stabilization, and delivery of siRNA molecules have greatly facilitated their therapeutic utility resulting in a diverse pipeline of siRNA therapeutics currently in clinical trials. In 2018, almost 20 years since the discovery of the RNAi pathway, the first siRNA-based drug was approved by the US Food and Drug Administration (FDA) for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis . In this review, we will describe the different chemical modifications used in siRNA drugs, summarize the currently deployed strategies for delivering siRNA therapeutics to the liver, and highlight recent advances in the development of siRNA therapeutics for the treatment of liver diseases.

<span style=color:blue>RNA干扰（RNAi）的发现以及使用合成的21-23核苷酸（nt）双链RNA（siRNA）在哺乳动物细胞中以序列特异性方式触发转录后基因沉默的应用，彻底改变了功能基因组学研究和生物医学研究。此外，siRNA分子的设计、化学稳定性和递送方面的显著改进，大大提高了其治疗效用，使得目前有多种siRNA治疗药物正在进行临床试验。2018年，距离RNAi途径发现近20年后，第一个基于siRNA的药物被美国食品药品监督管理局（FDA）批准用于治疗由遗传性转甲状腺素介导的淀粉样变性引起的多发性神经病。在这篇综述中，我们将介绍siRNA药物中使用的不同化学修饰，概述当前用于将siRNA药物递送到肝脏的策略，并强调在肝脏疾病治疗中siRNA药物开发的最新进展。</span>

## 2 Chemical Modifications in siRNA Drugs siRNA药物中的化学修饰

The endogenous RNAi machinery can be engaged by synthetic siRNA molecules to specifically silence the expression of a given target gene for therapeutics. However, unmodified siRNAs are large, polyanionic, and susceptible to degradation by nucleases, which make their clinical use difficult due to poor cellular uptake and rapid clearance in vivo. Furthermore, gene silencing by RNAi-based drugs requires optimization of the siRNA triggers for target specificity with minimized off-target effects and immunogenic reactions due to sensing of double-stranded RNA molecules by Toll-like receptor (TLR) 3/7/8 and protein kinase R (PKR), and for improved nuclease resistance. This can be achieved using a variety of chemical modifications of the sugar, the nucleobase, or the internucleotide linkages (Fig. 1). Commonly used 2′ sugar modifications in siRNA molecules include 2′-*O*-methyl (2′-*O*-Me) and 2′-fluoro (2′-F), which enhance serum stability and reduce immune activation of siRNA drugs (Fig. 1). In addition, structurally constrained bicyclic locked nucleic acids (LNA) and the flexible acyclic unlocked nucleic acids (UNA) have been deployed to increase or decrease, respectively, the binding affinity of siRNAs to their cognate target RNA. Moreover, substitution of phosphodiester linkages with phosphorothioate (PS) linkages, in which a sulfur atom replaces one of the non-bridging oxygen atoms in the phosphate group also improve nuclease resistance (Fig. 1). More recently, additional chemistries have been applied to enhance siRNA potency and safety. For example, incorporation of a 5′(*E*)-vinyl-phosphonate in the guide (antisense) strand improves the potency and duration of RNAi activity in vivo, while incorporation of a (*S*)-glycol nucleic acid  modification in the seed region of the siRNA guide strand decreases hepatotoxicity and further improves potency. In addition to the chemical modifications, selection of the siRNA sequence has a major impact on both on-target potency and off-targets activities. For instance, ensuring exclusive selection and loading of the guide strand into the RISC complex is crucial to minimize off-target activities. This can be reinforced by decreasing the thermodynamic stability of the 5′ end of the guide strand by selecting sequences with AU-rich motifs. Asymmetric siRNAs with a 2-nt 3′ overhang in one end and a blunt end in the other have also been reported to favor guide strand incorporation into the RISC complex. Finally, using LNAs allows the design of small internally segmented inferring RNAs (sisiRNAs), which are characterized by an intact guide strand and a segmented passenger (sense) strand modified with LNAs preventing loading into the RISC complex, thereby minimizing passenger-strand induced off-target effects.

<span style=color:blue>内源性RNA干扰（RNAi）机制可以通过合成的siRNA分子来启动，特异性地沉默特定靶基因的表达以用于治疗。然而，未修饰的siRNA分子较大且带有多阴离子，容易被核酸酶降解，这使得其在临床应用中面临细胞摄取效率低和体内快速清除的挑战。此外，RNAi药物的基因沉默效果需要对siRNA进行优化，以确保其靶向特异性，同时尽量减少脱靶效应和因双链RNA被Toll样受体（TLR）3/7/8和蛋白激酶R（PKR）感应而引起的免疫反应，并提高对核酸酶的抵抗力。通过对糖、碱基或核苷酸间连接进行各种化学修饰可以实现这一点（图1）。常用的siRNA分子中的2′位糖修饰包括2′-O-甲基（2′-O-Me）和2′-氟（2′-F），它们可以增强血清稳定性并减少siRNA药物的免疫激活（图1）。此外，结构受限的双环锁核酸（LNA）和灵活的无环解锁核酸（UNA）分别用于增加或减少siRNA与其靶RNA的结合亲和力。此外，用磷硫酰（PS）连接取代磷酸二酯连接，其中硫原子取代磷酸基团中的一个非桥氧原子，也能提高对核酸酶的抵抗力（图1）。最近，更多的化学修饰被应用于增强siRNA的效力和安全性。例如，在引导链（反义链）中加入5′(E)-乙烯基磷酸酯，可以提高RNAi活性在体内的效力和持续时间，而在siRNA引导链的种子区加入(S)-乙二醇核酸修饰则可以减少肝毒性并进一步提高效力。除了化学修饰，siRNA序列的选择对靶向效力和脱靶效应也有重大影响。例如，确保引导链被选择并独特地加载到RISC复合体中对于最小化脱靶效应至关重要。选择含有AU富集基序的序列可以降低引导链5′末端的热力学稳定性，从而加强这一点。据报道，具有一端2个核苷酸3′悬垂末端和另一端平末端的非对称siRNA也有助于引导链加载到RISC复合体中。最后，使用LNA可以设计小型内部分段干扰RNA（sisiRNA），其特点是完整的引导链和经过LNA修饰的分段乘客链（正义链），防止其加载到RISC复合体中，从而最小化乘客链引起的脱靶效应。</span>

![485053_1_En_5_Fig1_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_5_Fig1_HTML.png)

<span style=font-family:kaiti;text-align:center;>**Fig. 1** Structures of chemical modifications used in siRNA drugs. Commonly used sugar modifications in siRNA molecules include 2′-*O*-methyl (2′-*O*-Me), 2′-fluoro (2′-F), locked nucleic acid (LNA), and unlocked nucleic acid (UNA). Replacement of phosphate backbone linkages with phosphorothioate (PS) linkages increases nuclease resistance of siRNA<span style=color:blue>siRNA 药物中使用的化学修饰结构。siRNA 分子中常用的糖修饰包括 2′-O-甲基 (2′-O-Me)、2′-氟 (2′-F)、锁定核酸 (LNA) 和解锁核酸 (UNA)。用硫代磷酸酯 (PS) 键替换磷酸主链键可提高 siRNA 的核酸酶抗性</span></span>

The importance of chemical modifications in siRNA drugs is underscored by the results from the ENDEAVOUR Phase III clinical trial (Clinical Trial Number: NCT02319005). The study showed that revusiran, Alnylam’s first GalNAc-conjugated siRNA drug targeting transthyretin (TTR), had an imbalance in mortality with 18 deaths in the revusiran arm compared with only 2 deaths in the placebo group, as well as increased peripheral neuropathy. The design of revusiran is based on Alnylam’s Standard Template Chemistry (STC), in which the siRNA sequence is fully modified with 2′-OMe and 2′-F sugars and has two terminal PS backbone linkages at the 3′-end of the guide strand. To improve this siRNA drug design, Alnylam developed enhanced stability chemistry (ESC), which includes modifications improving metabolic stability, potency, and duration of action, resulting in decreased dose level and toxicity. The ESC modifications include among others PS backbone adjustments at the 5′-ends of both strands, structural motifs that extend the guide strand to 23 nt, and an augmented number of sequential 2′-*O*-Me modifications. Recently, Alnylam reported on the development of the ESC+ system that further improves the specificity and therapeutic index . All siRNA drugs from Alnylam entering clinical studies are based on the ESC or ESC+ design.

<span style=color:blue>在siRNA药物中进行化学修饰的重要性在ENDEAVOUR第三期临床试验（临床试验编号：NCT02319005l）的结果中得到了充分体现。该研究表明，Alnylam公司的第一个GalNAc-偶联siRNA药物revusiran，在治疗转甲状腺素（TTR）相关疾病时，revusiran组有18人死亡，而安慰剂组只有2人死亡，同时还观察到周围神经病变增加。revusiran的设计基于Alnylam的标准模板化学（STC），即siRNA序列完全由2′-OMe和2′-F糖修饰，并在引导链的3′端有两个末端磷硫酰（PS）骨架连接。为了改进这种设计，Alnylam开发了增强稳定性化学（ESC），包括提高代谢稳定性、效力和作用持续时间的修饰，从而降低了剂量水平和毒性。ESC修饰包括对两条链的5′端进行PS骨架调整，将引导链延长至23个核苷酸的结构模体，以及增加2′-OMe修饰的数量。最近，Alnylam公司报道了ESC+系统的开发，进一步提高了特异性和治疗指数。所有进入临床研究的Alnylam公司的siRNA药物都基于ESC或ESC+设计。</span>

## 3 Strategies for Delivering siRNA Drugs to the Liver siRNA药物肝脏递送策略

Development of siRNA therapeutics holds great promise for the treatment of a wide array of human diseases. However, delivery of siRNA drugs is hampered by their high molecular weight (approximately 13–15 kDa) and hydrophilic and polyanionic properties, which prevent naked siRNA molecules to cross the cell membrane. Liver is an attractive organ for the development of siRNA therapeutics since it is amenable to both passive and targeted delivery of siRNAs drugs. Passive delivery exploits the inherent tendency of liposomes and lipid nanoparticles to accumulate in filtering organs of the reticuloendothelial system (RES), primarily the liver, but also lymph nodes, kidney, and spleen. Targeted delivery of siRNAs takes advantage of the asialoglycoprotein receptor (ASGPR), which is expressed at high density on the surface of hepatocytes. Thus, a key focus of RNAi therapeutics has been to develop siRNA drugs for treating liver diseases. Below, we will discuss some representative delivery systems used in the development of siRNA therapeutics for the treatment of liver diseases (Fig. 2).

<span style=color:blue>siRNA治疗的发展在治疗各种人类疾病方面展现了巨大潜力。然而，由于siRNA药物的高分子量（大约13–15 kDa）及其亲水性和多阴离子特性，使得裸露的siRNA分子难以穿越细胞膜，从而阻碍了其递送。肝脏是siRNA治疗开发的理想靶器官，因为它适合于siRNA药物的被动和靶向递送。被动递送利用脂质体和脂质纳米颗粒在网状内皮系统（RES）过滤器官中积累的固有趋势，主要是肝脏，也包括淋巴结、肾脏和脾脏。siRNA的靶向递送则利用了在肝细胞表面高密度表达的去唾液酸糖蛋白受体（ASGPR）。因此，RNA干扰疗法的一个关键重点是开发用于治疗肝脏疾病的siRNA药物。以下，我们将讨论一些用于开发肝病治疗siRNA药物的典型递送系统（图2）。</span>

![485053_1_En_5_Fig2_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_5_Fig2_HTML.png)

<span style=font-family:kaiti;text-align:center;>**Fig. 2** Schematic illustration showing receptor-mediated and passive delivery of siRNAs drugs to the liver. Conjugation of the triantennary GalNAc ligand to the passenger strand of an siRNA enhances delivery to the liver. The siRNA molecule enters the hepatocyte by receptor-mediated endocytosis, where GalNAc binds to the asialoglycoprotein receptor (ASGPR). Upon internalization, the siRNA molecule escapes from the endosome and the guide strand (antisense) is incorporated into the RNA-induced silencing complex (RISC). Lipid nanoparticles (LNPs) facilitate siRNA delivery into the cytoplasm of target cells (hepatocytes) following intravenous (i.v.) administration. Passive delivery benefits from the propensity of LNPs to accumulate in filtering organs of the reticuloendothelial system, including the liver. The LNP encapsulated-siRNA system exploits different lipid components (e.g., PEG-lipid, DSPC, ionizable cationic lipid, and cholesterol) to increase uptake and thereby gene silencing through the RNAi pathway<span style=color:blue>示意图显示了受体介导和被动递送 siRNA 药物至肝脏的过程。三天线 GalNAc 配体与 siRNA 的过客链结合可增强向肝脏的递送。siRNA 分子通过受体介导的内吞作用进入肝细胞，其中 GalNAc 与去唾液酸糖蛋白受体 (ASGPR) 结合。内化后，siRNA 分子从内体中逃逸，引导链 (反义) 被整合到 RNA 诱导的沉默复合物 (RISC) 中。脂质纳米颗粒 (LNP) 有助于在静脉 (i.v.) 给药后将 siRNA 递送到靶细胞 (肝细胞) 的细胞质中。被动递送受益于 LNP 倾向于在网状内皮系统的过滤器官（包括肝脏）中积累。 LNP 封装的 siRNA 系统利用不同的脂质成分（例如 PEG 脂质、DSPC、可电离阳离子脂质和胆固醇）来增加吸收，从而通过 RNAi 途径实现基因沉默</span></span>

### 3.1 Lipid Nanoparticles 脂质纳米粒

Lipid nanoparticles (LPNs) have been successfully deployed to deliver siRNA drugs to the liver. Many pharmaceutical companies have developed LNP-based delivery systems typically consisting of 20–200 nm regular LNP structures with a siRNA encapsulation efficiency of over 90%. Using helper lipids such as distearoylphosphatidylcholine (DSPC), DMG-PEG2000, and cholesterol, robust gene silencing in the liver is achievable via the enhanced permeability and retention effect, and penetrate leaky or more permeable vasculature. Consequently, most of the pharmaceutical companies have focused on developing siRNA drugs targeting hepatic genes (Table 1).

<span style=color:blue>脂质纳米颗粒（LNPs）已成功应用于将siRNA药物递送至肝脏。许多制药公司开发了基于LNP的递送系统，通常由20-200纳米的规则LNP结构组成，siRNA包封效率超过90%。通过使用如二硬脂酰磷脂酰胆碱（DSPC）、DMG-PEG2000和胆固醇等辅助脂质，通过增强的渗透性和滞留效应，可以在肝脏中实现强有力的基因沉默，并穿透渗漏或更具渗透性的血管。因此，大多数制药公司都专注于开发针对肝脏基因的siRNA药物（表1）。</span>

**Table 1** siRNA drugs in clinical development for treatment of liver diseases

<div class="c-table-scroll-wrapper__content c-table-scroll-wrapper__fade" data-component-scroll-wrapper=""><table class="data last-table"><thead class="c-article-table-head"><tr><th class="u-text-left "><p>Drug</p></th><th class="u-text-left "><p>Indication(s)</p></th><th class="u-text-left "><p>Target(s)</p></th><th class="u-text-left "><p>Chemical modifications</p></th><th class="u-text-left "><p>Delivery system</p></th><th class="u-text-left "><p>Sponsor</p></th><th class="u-text-left "><p>Clinical phase</p></th><th class="u-text-left "><p>Status</p></th><th class="u-text-left "><p>NCT number</p></th></tr></thead><tbody><tr><td colspan="9"><p><i>Cardio-metabolic and endocrinological disease</i></p></td></tr><tr><td class="u-text-left "><p>Onpattro (Patisiran, ALN-TTR02)</p></td><td class="u-text-left "><p>TTR-mediated amyloidosis</p></td><td class="u-text-left "><p>TTR</p></td><td class="u-text-left "><p>2′-OMe, 2′-F</p></td><td class="u-text-left "><p>LNP</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>III, approved</p></td><td class="u-text-left "><p>Commercialized</p></td><td class="u-text-left "><p>NCT02939820</p></td></tr><tr><td class="u-text-left "><p>Givosiran (ALN-AS1)</p></td><td class="u-text-left "><p>Acute hepatic porphyrias</p></td><td class="u-text-left "><p>ALAS1</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>III, approved</p></td><td class="u-text-left "><p>Commercialized</p></td><td class="u-text-left "><p>NCT03338816</p></td></tr><tr><td class="u-text-left "><p>Lumasiran (ALN-GO1)</p></td><td class="u-text-left "><p>Primary Hyperoxaluria type 1 (PH1)</p></td><td class="u-text-left "><p>HAO1</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>III</p></td><td class="u-text-left "><p>Active, not recruiting</p></td><td class="u-text-left "><p>NCT03681184</p></td></tr><tr><td class="u-text-left "><p>Vutrisiran (ALN-TTRsc02)</p></td><td class="u-text-left "><p>Amyloidosis</p></td><td class="u-text-left "><p>TTR</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>III</p></td><td class="u-text-left "><p>Active, not recruiting</p></td><td class="u-text-left "><p>NCT03759379</p></td></tr><tr><td class="u-text-left "><p>Inclisiran (ALN-PCSsc)</p></td><td class="u-text-left "><p>Hypercholesterolemia</p></td><td class="u-text-left "><p>PCSK9</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals/The Medicine Company</p></td><td class="u-text-left "><p>III</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03705234</p></td></tr><tr><td class="u-text-left "><p>Revusiran (ALN-TTRsc)</p></td><td class="u-text-left "><p>Amyloidosis</p></td><td class="u-text-left "><p>TTR</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>III</p></td><td class="u-text-left "><p>Completed</p></td><td class="u-text-left "><p>NCT02319005</p></td></tr><tr><td class="u-text-left "><p>ALN-AAT02</p></td><td class="u-text-left "><p>Alpha-1 liver disease</p></td><td class="u-text-left "><p>AAT</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>I/II</p></td><td class="u-text-left "><p>Active, not recruiting</p></td><td class="u-text-left "><p>NCT03767829</p></td></tr><tr><td class="u-text-left "><p>PRO-040201</p></td><td class="u-text-left "><p>Hypercholesterolemia</p></td><td class="u-text-left "><p>ApoB</p></td><td class="u-text-left "><p>Unmodified</p></td><td class="u-text-left "><p>LNP</p></td><td class="u-text-left "><p>Arbutus biopharma corporation</p></td><td class="u-text-left "><p>I/II</p></td><td class="u-text-left "><p>Terminated</p></td><td class="u-text-left "><p>NCT00927459</p></td></tr><tr><td class="u-text-left "><p>AMG 890 (ARO-LPA)</p></td><td class="u-text-left "><p>Cardiovascular disease</p></td><td class="u-text-left "><p>LPA</p></td><td class="u-text-left "><p>Undisclosed</p></td><td class="u-text-left "><p>TRiM (GalNAc-siRNA conjugate)</p></td><td class="u-text-left "><p>Arrowhead pharmaceuticals/Amgen</p></td><td class="u-text-left "><p>II</p></td><td class="u-text-left "><p>Not recruiting</p></td><td class="u-text-left "><p>NCT04270760</p></td></tr><tr><td class="u-text-left "><p>Nedosiran (DCR-PHXC)</p></td><td class="u-text-left "><p>Primary Hyperoxaluria</p></td><td class="u-text-left "><p>HAO1</p></td><td class="u-text-left "><p>Undisclosed</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Dicerna pharmaceuticals</p></td><td class="u-text-left "><p>III</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT04042402</p></td></tr><tr><td class="u-text-left "><p>ARO-ANG3</p></td><td class="u-text-left "><p>Hypertriglyceridemia</p></td><td class="u-text-left "><p>ANGPTL3</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F, inverted base</p></td><td class="u-text-left "><p>TRiM (GalNAc-siRNA conjugate)</p></td><td class="u-text-left "><p>Arrowhead pharmaceuticals</p></td><td class="u-text-left "><p>I</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03747224</p></td></tr><tr><td class="u-text-left "><p>ARO-APOC3</p></td><td class="u-text-left "><p>Hypertriglyceridemia, familial Chylomicronemia</p></td><td class="u-text-left "><p>ApoC3</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F, inverted base</p></td><td class="u-text-left "><p>TRiM (GalNAc-siRNA conjugate)</p></td><td class="u-text-left "><p>Arrowhead pharmaceuticals</p></td><td class="u-text-left "><p>I</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03783377</p></td></tr><tr><td class="u-text-left "><p>ARO-AAT</p></td><td class="u-text-left "><p>Alpha-1 antitrypsin deficiency</p></td><td class="u-text-left "><p>AAT</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F, inverted base</p></td><td class="u-text-left "><p>TRiM (GalNAc-siRNA conjugate)</p></td><td class="u-text-left "><p>Arrowhead pharmaceuticals</p></td><td class="u-text-left "><p>II/III</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03945292</p></td></tr><tr><td class="u-text-left "><p>ARO-HSD</p></td><td class="u-text-left "><p>Non-alcoholic steatohepatitis</p></td><td class="u-text-left "><p>HSD17B13</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F, inverted base</p></td><td class="u-text-left "><p>TRiM (GalNAc-siRNA conjugate)</p></td><td class="u-text-left "><p>Arrowhead pharmaceuticals</p></td><td class="u-text-left "><p>I</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT04202354</p></td></tr><tr><td colspan="9"><p><i>Infectious disease</i></p></td></tr><tr><td class="u-text-left "><p>ARB-001467</p></td><td class="u-text-left "><p>Hepatitis B</p></td><td class="u-text-left "><p>HBV gene</p></td><td class="u-text-left "><p>Undisclosed</p></td><td class="u-text-left "><p>LNP</p></td><td class="u-text-left "><p>Arbutus biopharma corporation</p></td><td class="u-text-left "><p>II</p></td><td class="u-text-left "><p>Completed</p></td><td class="u-text-left "><p>NCT02631096</p></td></tr><tr><td class="u-text-left "><p>JNJ-3989 (ARO-HBV)</p></td><td class="u-text-left "><p>Hepatitis B</p></td><td class="u-text-left "><p>HBV gene</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F, inverted base</p></td><td class="u-text-left "><p>TRiM (GalNAc-siRNA conjugate)</p></td><td class="u-text-left "><p>Arrowhead pharmaceuticals/Janssen</p></td><td class="u-text-left "><p>I/II</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03365947</p></td></tr><tr><td class="u-text-left "><p>DCR-HBVS (RG6346)</p></td><td class="u-text-left "><p>Hepatitis B</p></td><td class="u-text-left "><p>HBV gene</p></td><td class="u-text-left "><p>Undisclosed</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Dicerna pharmaceuticals</p></td><td class="u-text-left "><p>I</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03772249</p></td></tr><tr><td class="u-text-left "><p>ALN-HBV</p></td><td class="u-text-left "><p>Hepatitis B</p></td><td class="u-text-left "><p>HBV gene</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>I</p></td><td class="u-text-left "><p>Terminated</p></td><td class="u-text-left "><p>NCT02826018</p></td></tr><tr><td class="u-text-left "><p>ALN-HBV02 (VIR-2218)</p></td><td class="u-text-left "><p>Hepatitis B</p></td><td class="u-text-left "><p>HBV gene</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals/Vir Biotechnology</p></td><td class="u-text-left "><p>I/II</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03672188</p></td></tr><tr><td class="u-text-left "><p>TKM-100802</p></td><td class="u-text-left "><p>Ebola</p></td><td class="u-text-left "><p>VP24, VP35, Zaire Ebola L-polymerase</p></td><td class="u-text-left "><p>Undisclosed</p></td><td class="u-text-left "><p>LNP</p></td><td class="u-text-left "><p>Arbutus biopharma corporation</p></td><td class="u-text-left "><p>I</p></td><td class="u-text-left "><p>Terminated</p></td><td class="u-text-left "><p>NCT02041715</p></td></tr><tr><td colspan="9"><p><i>Cancer</i></p></td></tr><tr><td class="u-text-left "><p>TKM-080301</p></td><td class="u-text-left "><p>Hepatocellular carcinoma</p></td><td class="u-text-left "><p>PLK1</p></td><td class="u-text-left "><p>Undisclosed</p></td><td class="u-text-left "><p>LNP</p></td><td class="u-text-left "><p>Arbutus biopharma corporation</p></td><td class="u-text-left "><p>I/II</p></td><td class="u-text-left "><p>Completed</p></td><td class="u-text-left "><p>NCT02191878</p></td></tr><tr><td class="u-text-left "><p>DCR-MYC</p></td><td class="u-text-left "><p>Hepatocellular carcinoma</p></td><td class="u-text-left "><p>MYC</p></td><td class="u-text-left "><p>Undisclosed</p></td><td class="u-text-left "><p>LNP</p></td><td class="u-text-left "><p>Dicerna pharmaceuticals</p></td><td class="u-text-left "><p>I/II</p></td><td class="u-text-left "><p>Terminated, has results</p></td><td class="u-text-left "><p>NCT02314052</p></td></tr><tr><td class="u-text-left "><p>ALN-VSP02</p></td><td class="u-text-left "><p>Solid tumors, incl. Liver cancer</p></td><td class="u-text-left "><p>VEGF, KSP</p></td><td class="u-text-left "><p>2′-OMe, PS</p></td><td class="u-text-left "><p>LNP</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>I</p></td><td class="u-text-left "><p>Completed</p></td><td class="u-text-left "><p>NCT00882180</p></td></tr><tr><td colspan="9"><p><i>Others</i></p></td></tr><tr><td class="u-text-left "><p>Fitusiran (ALN-AT3sc)</p></td><td class="u-text-left "><p>Hemophilia</p></td><td class="u-text-left "><p>AT</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Genzyme/Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>III</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03417245</p></td></tr><tr><td class="u-text-left "><p>Cemdisiran (ALN-CC5)</p></td><td class="u-text-left "><p>Typical hemolytic uremic syndrome</p></td><td class="u-text-left "><p>C5</p></td><td class="u-text-left "><p>PS, 2′-OMe, 2′-F</p></td><td class="u-text-left "><p>GalNAc-siRNA conjugate</p></td><td class="u-text-left "><p>Alnylam Pharmaceuticals</p></td><td class="u-text-left "><p>II</p></td><td class="u-text-left "><p>Recruiting</p></td><td class="u-text-left "><p>NCT03841448</p></td></tr></tbody></table></div>

LNPs are divided into two major groups based on the different properties of the key lipids used: (1) cationic LNPs and (2) ionizable cationic LNPs. The positively charged cationic LNPs interact by electrostatic interactions with the polyanionic siRNA, leading to formation of siRNA lipocomplexes with enhanced cellular uptake and endosomal escape. Ionizable cationic LNPs were developed to achieve a system, where efficient encapsulation of negatively charged siRNAs could be accomplished at low pH, but which also exhibited a relatively uncharged surface at pH 7.4. Interestingly, apolipoprotein E (ApoE) was reported to function as a targeting ligand in an LDL-receptor-dependent manner for ionizable cationic LNPs , thereby enhancing hepatic delivery (Fig. 2) .

<span style=color:blue>脂质纳米颗粒（LNPs）根据所使用的关键脂质的不同性质分为两大类：（1）阳离子LNPs和（2）可离子化阳离子LNPs。带正电的阳离子LNPs通过静电相互作用与聚阴离子siRNA相互作用，形成具有增强细胞摄取和内吞体逃逸能力的siRNA脂质复合物。可离子化阳离子LNPs的开发旨在实现一种系统，在低pH值下能够有效封装带负电的siRNA，但在pH 7.4时表现出相对无电荷的表面。有趣的是，有报道指出载脂蛋白E（ApoE）作为靶向配体通过低密度脂蛋白受体（LDL受体）依赖的方式作用于可离子化阳离子LNPs，从而增强肝脏递送（图2）</span>

### 3.2 Dynamic Polyconjugates 动态多聚缀合物

The first dynamic polyconjugates (DPC) for targeted in vivo delivery of siRNA triggers to the liver were developed by Rozema and coworkers. DPCs comprise four important parts: a delivery platform that can reversibly conjugate a polymer (or polypeptide) with the siRNA, a hepatocyte targeting ligand (*N*-acetylgalactosamine (GalNAc)), a shielding agent (PEG fragment) to elongate blood retention, and a hydrophobic lipid for enhanced interaction with the cell membrane.

<span style=color:blue>Rozsema 及其同事开发了用于 siRNA 触发物靶向肝脏内递送的首个动态聚合物缀合物 (DPC)。DPC 由四部分组成：一是递送平台，能够可逆地将聚合物 (或多肽) 与 siRNA 连接起来；二是肝细胞靶向配体 N-乙酰氨基葡萄糖 (GalNAc)，负责特异识别肝细胞；三是聚乙二醇 (PEG) 片段，作为屏蔽剂延长药物在血液中的停留时间；四是疏水脂质，能增强药物与细胞膜的相互作用，促进细胞摄取。</span>

The second generation of Dynamic PolyConjugate technology (DPC 2.0) developed by Arrowhead Pharmaceuticals relies on cholesterol modifications to facilitate membrane penetration. In this system, a cholesterol-modified siRNA (chol-siRNA) is co-injected with a GalNAc-masked polypeptide due to the ease of manufacturing of the two components separately instead of a single molecule. However, frequent injections with simultaneous delivery of the siRNA trigger and the helper molecules to the target cells involve separate and sequential entry of the components into the blood. Moreover, safety issues, especially immunogenicity, might be a concern due to recognition by TLR 3/7/8 and/or PKR.

<span style=color:blue>Arrowhead Pharmaceuticals 公司研发的第二代动态聚合物缀合物技术 (DPC 2.0) 利用胆固醇修饰 siRNA (chol-siRNA) 来增强细胞膜的穿透力，简化了生产工艺。该系统采用单独注射胆固醇修饰的 siRNA 和 GalNAc 修饰的多肽，分别靶向 siRNA 和肝细胞，但这种方式需要频繁注射，siRNA 触发物和辅助分子需要分两次进入血液，过程复杂。另外，由于这种方法可能会被 TLR 3/7/8 和/或 PKR 等免疫识别系统识别，导致免疫原性，因此安全性也存在潜在的隐患。</span>

### 3.3 GalNAc-siRNA Conjugates GalNAc-siRNA缀合物

A major breakthrough in RNAi medicine was the discovery of targeted delivery of siRNA drugs to hepatocytes via ASGPR in the liver. An oligosaccharide termed GalNAc has high affinity toward the ASGPR receptor allowing selective delivery of GalNAc-siRNA conjugates to hepatocytes. The use of GalNAc-conjugated siRNAs for liver-targeted delivery is based on binding of the GalNAc moiety to the ASGPR on hepatocytes, which contain ∼500,000 receptors per cell, resulting in rapid endocytosis. ASGPR was discovered in 1965 by Ashwell and Morell, and shown to be predominantly expressed in hepatocytes, but not in other liver cells, such as Kupffer cells. Furthermore, GalNAc, which is an amino sugar derivative of galactose, was shown to possess high affinity to ASGPR. Binding of GalNAc to ASGPR occurs at the sinusoidal surface of the hepatocyte, initially on diffuse monomeric ASGPR receptors, followed by rapid local aggregation of the GalNAc-ASGPR complexes, and larger scale aggregation in clathrin-coated pits, resulting in endocytosis. Early studies noted that the half-life of ASGPR was much longer than the bound asialoglycoproteins. Subsequent studies showed that acidification during endosomal maturation leads to dissociation of the GalNAc ligand from ASGPR followed by degradation of GalNAc in the lysosome and rapid recycling of ASGPR to the cell surface. Several studies have demonstrated that the GalNAc moiety is able to facilitate efficient cellular uptake of GalNAc-siRNA conjugates by hepatocytes via ASGPR-mediated and clathrin-involved endocytosis, resulting in effective gene silencing with minimal adverse effects (Fig.  2) .

<span style=color:blue>RNAi 药物领域的一大进步是利用 ASGPR 靶向将 siRNA 药物递送至肝细胞。一种叫做 GalNAc 的寡糖分子可以特异性地结合肝细胞表面的 ASGPR 受体，从而让携带 GalNAc 的 siRNA 复合物 (GalNAc-siRNA) 优先进入肝细胞。GalNAc 辅助的肝脏靶向递送方法依赖于 GalNAc 与肝细胞上丰富的 ASGPR 受体 (每个肝细胞约有 50 万个) 的结合，从而促进 siRNA 的快速细胞内吞作用。ASGPR 受体于 1965 年由 Ashwell 和 Morell 发现，主要表达于肝细胞，在其他肝脏细胞 (例如 Kupffer 细胞) 中几乎没有表达。GalNAc 是半乳糖的一种衍生物，也被称为氨基糖，研究表明它与 ASGPR 受体具有很高的亲和力。GalNAc 与 ASGPR 的结合发生在肝细胞面向血液的窦状面上，最初结合分散的单体 ASGPR 受体，然后迅速聚集形成局部复合物，并进一步聚集于包含网格蛋白的凹陷处，最终通过内吞作用进入细胞。早期研究发现，结合了 asialoglycoprotein 的 ASGPR 受体比游离受体具有更长的半衰期。后续研究表明，内吞体成熟过程中酸化会导致 GalNAc 配体从 ASGPR 上解离，GalNAc 在溶酶体中降解，而 ASGPR 则被迅速循环回细胞表面。有多项研究表明，GalNAc 可以促进 GalNAc-siRNA 复合物通过 ASGPR 介导的网格蛋白依赖性内吞作用有效进入肝细胞，从而实现基因沉默并具有良好的安全性 (见图 2)。</span>

## 4 Development of siRNA Drugs for Treatment of Liver Diseases 治疗肝病的siRNA药物开发

Due to the recent progress in liver-targeted delivery of siRNA therapeutics , many biopharmaceutical companies have established extensive pipelines focused on the treatment of liver-related diseases. There are currently 27 siRNA drugs in clinical trials for treating liver diseases such as hypercholesterolemia, hemophilia, hepatic porphyria, amyloidosis, and primary hyperoxaluria (Table 1). Three pharmaceutical companies, Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, and Alnylam Pharmaceuticals, have GalNAc-conjugated siRNA drugs for liver diseases in phase II/III and phase III trials. Dicerna has three siRNA drugs in clinical trials, including a phase III study of nedosiran (formerly known as DCR-PHXC) for the treatment of all three known types of primary hyperoxaluria (PH). The three known genetic types of PH result from mutations in three different genes, AGXT, GRHPR, and HOGA1, respectively, in the glyoxylate metabolism pathway, resulting in overproduction of oxalate. Nedosiran is a GalNAc-siRNA conjugate targeting the lactate dehydrogenase enzyme, which catalyzes the final common step of the glyoxylate metabolism pathway, and thereby prevents overproduction of oxalate. Knockdown of LDH occurs specifically in hepatocytes due to the GalNAc ligand in nedosiran. Data from a phase III study showed a mean reduction in urinary oxalate of 48% (range: 28–59%) among participants with PH1 receiving a single 1.5 mg/kg dose, which led to normalization or near-normalization in the participants, whereas patients with PH2 showed a mean reduction of 24-h urinary oxalate of 42% (range: 22–66%). Nedosiran was generally well tolerated with mild or moderate injection site reactions.

<span style=color:blue>由于siRNA治疗靶向肝脏递送的最新进展，许多生物制药公司已建立了专注于治疗肝脏相关疾病的广泛管线。目前有27种siRNA药物正在临床试验中，用于治疗高胆固醇血症、血友病、肝性卟啉病、淀粉样病和原发性高草酸尿症等肝脏疾病（见表1）。Dicerna Pharmaceuticals、Arrowhead Pharmaceuticals和Alnylam Pharmaceuticals三家制药公司在II/III期和III期试验中，开发了针对肝脏疾病的GalNAc 缀合 siRNA 药物。Dicerna在临床试验中有三种siRNA药物，包括nedosiran（曾用名DCR-PHXC）的III期研究，用于治疗所有三种已知的原发性高草酸尿症（PH）。这三种已知的PH遗传类型分别由三个不同的基因AGXT、GRHPR和HOGA1的突变引起，在乙醛酸代谢途径中导致草酸过度生产。Nedosiran是一个GalNAc-siRNA共轭物，靶向乳酸脱氢酶酶，该酶催化乙醛酸代谢途径的最后共同步骤，从而防止草酸的过度生成。由于nedosiran中的GalNAc配体，LDH的沉默特异性发生在肝细胞中。来自III期研究的数据显示，接受单剂量为1.5 mg/kg的PH1患者，尿草酸平均减少48%（范围：28-59%），使得参与者的尿草酸正常或接近正常水平，而PH2患者显示尿草酸24小时平均减少42%（范围：22-66%）。Nedosiran通常耐受良好，仅有轻度或中度的注射部位反应。</span>

Arrowhead Pharmaceuticals has six GalNAc-siRNA conjugates in clinical trials, which includes an ongoing phase II/III study of ARO-AAT for the treatment of the genetic disorder Alpha-1 antitrypsin deficiency (AATD). The most common AATD disease variant, the Z mutant, has a single amino acid substitution that results in accumulation of the mutant protein in globules inside the hepatocytes leading to fibrosis, cirrhosis, and an increased risk of hepatocellular carcinoma. ARO-AAT is a cholesterol-conjugated UNA-modified (chol-UNA) siRNA drug targeting the mutant alpha-1 antitrypsin (Z-AAT) for suppressing the liver disease associated with AATD. This siRNA drug is administered concomitantly with the delivery excipient ARC-EX1 containing hepatocyte-targeted GalNAc-conjugated melittin-like peptide, which does not form a complex with the siRNA drug. Results from clinical trial phase I reported a 76.1% reduction in serum AAT 4 weeks after a single 4 mg/kg ARO-AAT dose. No severe adverse events were reported, whereas mild adverse effects included chills in 75% of ARO-AAT group likely related to the infusion of ARC-AAT. The study is currently in phase II/III, where ARO-AAT is administered on day 1, 29, and 113, and every 84 days thereafter in a total of 120 AAT patients.

<span style=color:blue>Arrowhead Pharmaceuticals 公司拥有六款 GalNAc-siRNA 缀合物正在进行临床试验，其中包括一项针对遗传性疾病 Alpha-1 抗胰蛋白酶缺乏症 (AATD) 的 ARO-AAT 的 II/III 期临床试验。最常见的 AATD 疾病变体 Z 型突变具有单个氨基酸替换，导致突变蛋白在肝细胞内聚集形成球状体，并进一步导致肝纤维化、肝硬化和肝细胞癌风险增加。ARO-AAT 是一种胆固醇缀合的 UNA 修饰 (chol-UNA) siRNA 药物，靶向突变的 alpha-1 抗胰蛋白酶 (Z-AAT)，用于抑制与 AATD 相关的肝脏疾病。该 siRNA 药物与递送载体 ARC-EX1 联合给药，ARC-EX1 含有肝细胞靶向的 GalNAc 缀合的蜂毒素样肽，但不与 siRNA 药物形成复合物。I 期临床试验结果显示，单剂量 4 mg/kg ARO-AAT 治疗后 4 周，血清 AAT 减少 76.1%。未报告严重不良事件，轻度不良事件包括 ARO-AAT 组 75% 的患者出现寒战，这可能与 ARC-AAT 的输注有关。该研究目前处于 II/III 期，ARO-AAT 在第 1、29 和 113 天以及此后每 84 天共对 120 名 AAT 患者进行给药。</span>

Alnylam Pharmaceuticals has currently 12 siRNA drugs in its clinical development pipeline, of which 11 are GalNAc-siRNA conjugates for a wide variety of liver diseases. Inclisiran (ALN-PCSsc) is based on Alnylam’s ESC-GalNAc drug platform and targets the pro-protein convertase subtilisin-kexin type 9 (PCSK-9) for the treatment of patients with hypercholesterolemia by providing sustained reductions in low-density lipoprotein (LDL) cholesterol levels upon infrequent dosing. Inclisiran has completed three large double-blind, randomized, placebo-controlled phase III studies (ORION-9, ORION-10 and ORION-11), in which 300 mg of the drug was administered subcutaneously on day 1, day 90, followed by s.c. injections every 6 months, leading to a 51% reduction in LDL cholesterol after 1 year. The adverse effects were generally similar in the inclisiran group compared to the placebo group. However, more injection-site reactions (ISRs) occurred in the inclisiran treatment group compared to placebo, but all ISRs were mild and resolved over time. By comparison, hypercholesterolemia patients currently taking statins to lower their LDL cholesterol levels are required to dose every day. Inclisiran is being developed by The Medicines Company and is expected to achieve regulatory approval in the USA and Europe in 2020.

<span style=color:blue>Alnylam Pharmaceuticals目前在其临床开发管线中有12种siRNA药物，其中11种是GalNAc-siRNA共轭物，用于治疗各种肝病。Inclisiran（ALN-PCSsc）基于Alnylam的ESC-GalNAc药物平台，靶向前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型（PCSK-9），用于治疗高胆固醇血症患者，通过间断给药持续降低低密度脂蛋白（LDL）胆固醇水平。Inclisiran已完成三项大型双盲、随机、安慰剂对照的III期研究（ORION-9、ORION-10和ORION-11），在这些研究中，药物在第1天和第90天皮下注射300 mg，之后每6个月注射一次，导致1年后LDL胆固醇降低了51%。不良反应在Inclisiran组与安慰剂组相比通常相似。然而，与安慰剂相比，Inclisiran治疗组的注射部位反应（ISRs）更多，但所有ISRs均为轻度，并随时间解决。相比之下，目前服用他汀类药物治疗高胆固醇血症患者需要每天服药。Inclisiran由The Medicines Company开发，预计将于2020年在美国和欧洲获得监管批准。</span>（注：该药物已经获得批准）

Lumasiran (ALN-GO1) is an investigational, s.c.-administered GalNAc-conjugated siRNA drug targeting hydroxyacid oxidase 1 (*HAO1*) for the treatment of Primary Hyperoxaluria Type 1 (PH1). PH1 is a rare disease, which leads to the formation of painful and recurrent kidney stones and nephrocalcinosis caused by excessive oxalate production resulting in the deposition of calcium oxalate crystals in the kidneys and urinary tract. Renal damage is caused by a combination of tubular toxicity from oxalate, calcium oxalate deposition in the kidneys, and urinary obstruction by calcium oxalate stones. Although a small subset of patients manages the disease with vitamin B6 treatment, the only effective treatment is a combined liver-kidney transplant, which requires life-long immune suppression and carries a significant mortality risk. Results from the ILLUMINATE A phase III study showed significant reduction of oxalate after monthly doses of lumasiran (3 mg/kg) for 3 months followed by quarterly maintenance doses. There were no severe adverse events in the study, and lumasiran was generally well tolerated. Alnylam is also conducting ILLUMINATE B and C, which are studies of lumasiran given to PH1 patients less than 6 years of age and PH1 patients of all ages with advanced renal disease, respectively. Results are expected in 2020 and 2021. Earlier this year, Alnylam Pharmaceuticals and Dicerna announced that they have executed a cross-license agreement of their respective intellectual property for lumasiran and nedosiran investigational programs. Moreover, the two companies have decided to form a development and commercialization collaboration on siRNA drugs for the treatment of alpha-1 liver diseases.

<span style=color:blue>Lumasiran (ALN-GO1) 是一种正在研究中的皮下注射 GalNAc 缀合 siRNA 药物，靶向羟基酸氧化酶 1 (*HAO1*)，用于治疗原发性高草酸尿症 1 型 (PH1)。PH1 是一种罕见疾病，由于过量草酸盐生成导致肾脏和尿路中草酸钙晶体沉积，从而形成疼痛性复发性肾结石和肾钙质沉着症。肾脏损伤是由草酸盐对肾小管的毒性、肾脏中草酸钙沉积以及草酸钙结石引起尿路梗阻共同造成的。虽然一小部分患者可以通过维生素 B6 治疗控制病情，但唯一有效的治疗方法是联合肝肾移植，该手术需要终身免疫抑制治疗，并伴有显着的死亡风险。III 期临床研究 ILLUMINATE A 的结果显示，每月剂量 (3 mg/kg) 的 lumasiran 连续使用 3 个月，然后按季度进行维持剂量治疗，可以显著降低尿液草酸盐水平。该研究中没有出现严重不良事件，lu masiran 耐受性良好。Alnylam 公司还在进行 ILLUMINATE B 和 C 研究，分别评估 lumasiran 在 6 岁以下 PH1 患者和所有年龄段晚期肾病 PH1 患者中的安全性及疗效。研究结果预计分别于 2020 年和 2021 年公布。今年年初，Alnylam Pharmaceuticals 和 Dicerna 公司宣布，双方就各自的 lumasiran 和 nedosiran 研究项目知识产权达成交叉许可协议。此外，两家公司决定合作开发和商业化用于治疗 alpha-1 肝脏疾病的 siRNA 药物。</span>

Vutrisiran (ALN-TTRsc02) is a s.c.-administered, investigational GalNAc-siRNA conjugate targeting transthyretin (TTR) for the treatment of transthyretin-mediated (ATTR) amyloidosis. Vutrisiran is similar to the already approved patisiran, but utilizes the GalNAc delivery platform instead of LNPs. Data from clinical phase I showed a TTR knockdown of 83% after a single 25 mg dose of vutrisiran, and a good safety profile with no severe adverse events. The safety and efficacy of vutrisiran are currently being evaluated in the HELIOS Phase III clinical program. Patients will receive either s.c.-administered vutrisiran (total dose of 25 mg every 3 months) (*n* = 120) or intravenously (i.v.) administered patisiran (0.3 mg/kg every 3 weeks) (*n* = 40) during a treatment period of 18 months. Results from the vutrisiran study will be evaluated with the placebo arm from the APOLLO study for most endpoints, which evaluated the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy.

<span style=color:blue>Vutrisiran (ALN-TTRsc02) 是一种皮下注射的正在研究中的 GalNAc-siRNA 缀合物，靶向转甲状蛋白 (TTR) 用于治疗转甲状蛋白介导的 (ATTR) 淀粉样变性病。Vutrisiran 与已经获批的 patisiran 相似，但使用 GalNAc 递送平台替代脂质纳米颗粒 (LNPs)。I 期临床试验数据显示，单剂量 25mg 的 vutrisiran 可使 TTR 敲除 83%，安全性良好，无严重不良事件。vutrisiran 的安全性和有效性目前正在 HELIOS III 期临床项目中评估。患者将在 18 个月的治疗期间接受皮下注射 vutrisiran (总剂量 25mg，每 3 个月一次) (*n* = 120) 或静脉注射 patisiran (0.3mg/kg，每 3 周一次) (*n* = 40)。vutrisiran 研究的大多数终点将与 APOLLO 研究的安慰剂组进行评估，APOLLO 研究评估了 patisiran 在患有 hATTR 淀粉样变性多发性神经病变的患者中的疗效和安全性。</span>

Fitusiran (ALN-AT3sc) targets anti-thrombin 3 (AT3) to enhance thrombin generation (TG) and rebalance hemostasis in patients with hemophilia A (HA) or hemophilia B (HB) with or without inhibitors for the treatment of hemophilia and rare bleeding disorders. Hemophilia is caused by a mutation in the F8 and F9 genes encoding the coagulation factors VIII (FVIII:C) and IX (FIX:C), respectively. Anti-thrombin (AT) is the naturally occurring inhibitor of thrombin, and patients with AT deficiency exhibit a clinically hypercoagulable state leading to thromboembolic events. Moreover, hemophilia patients with a concomitant AT deficiency have less severe bleeding phenotypes compared to patients with normal levels of AT. Fitusiran is administered s.c. once a month, and Phase I and II data showed dose-dependent lowering of AT (20%), increased TG, and a decrease in the frequency of spontaneous and traumatic bleeds. Fitusiran is currently in clinical phase III studies and is being developed by Sanofi Genzyme deploying Alnylam’s ESC-GalNAc siRNA drug platform.

<span style=color:blue>Fitusiran (ALN-AT3sc) 是一种靶向抗凝血酶 III 型 (AT3) 的 siRNA 药物，通过皮下注射给药，每月一次。该药物的作用原理是增强凝血酶生成 (TG)，从而重建血友病 A (HA) 或血友病 B (HB) 患者 (无论伴有或不伴有抑制物) 的止血平衡，用于治疗血友病和罕见出血性疾病。血友病是一种遗传性出血性疾病，由 F8 和 F9 基因突变引起，这两种基因分别编码凝血因子 VIII (FVIII:C) 和 IX (FIX:C)。抗凝血酶 (AT) 是人体内的一种天然凝血酶抑制物，AT 缺乏的患者会出现异常的高凝状态，容易形成血栓。而对于血友病患者来说，如果同时伴有 AT 缺乏，出血症状反而会轻一些。Fitusiran 的 I 期和 II 期临床试验数据显示，该药物可以剂量依赖性地降低 AT 水平 (约 20%)，同时增加凝血酶生成，并减少患者自发性出血和外伤性出血的发生频率。Fitusiran 目前正处于 III 期临床研究阶段，由赛诺菲基因泰克公司开发，并采用了 Alnylam 公司的 ESC-GalNAc siRNA 药物平台。</span>

## 5 FDA-Approved siRNA Drugs for the Treatment of Liver Diseases FDA 批准用于治疗肝病的 siRNA 药物

There are currently two FD-approved siRNA drugs on the market, patisiran (ONPATTRO™) for the treatment of hereditary transthyretin amyloidosis (hATTR) and givosiran (GIVLAARI™) for the treatment of acute hepatic porphyria (AHP), respectively (Fig. 3). Patisiran was approved in 2018 by the FDA for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis and is the first FDA-approved siRNA drug. It is an LNP-encapsulated siRNA targeting transthyretin (TTR) for the treatment of hATTR. hATTR is an autosomal dominant, progressive, life-threatening multisystem disease caused by mutations in the gene encoding TTR. Both mutant and wild-type transthyretin deposit as amyloids in peripheral nerves and the heart, kidney, and gastrointestinal tract, resulting in polyneuropathy and cardiomyopathy. TTR is mainly produced in the liver and forms homotetramers that transport retinol, thyroxine, and vitamin A. The absence of this protein results in vitamin A deficiency, and thus vitamin A is required as a daily supplement. However, if the protein is present, but misfolded, as occurs subsequent to its mutation in hATTR patients, it generates amyloid fibrils, which deposit in various organs. Treatment options for hATTR prior to the approval of patisiran included orthotopic liver transplantation or the administration of TTR tetramer stabilizing drugs such as tafamidis or diflunisal. However, many patients continue to have disease progression.

<span style=color:blue>目前已经有两种 siRNA 药物获批上市，分别为：治疗遗传性转甲状蛋白淀粉样变性病 (hATTR) 的 patisiran (商品名：ONPATTRO™) 和治疗急性肝卟啉病 (AHP) 的 givosiran (商品名：GIVLAARI™) (见图 3)。Patisiran 是史上首个获得 FDA 批准上市的 siRNA 药物，获批时间为 2018 年，用于治疗由遗传性转甲状蛋白介导的周围神经病变。Patisiran 是一种利用脂质纳米颗粒 (LNP) 递送的 siRNA 药物，靶向转甲状蛋白 (TTR)，用于治疗 hATTR。hATTR 是一种常染色体显性遗传病，由编码转甲状蛋白的基因突变引起，是一种进行性、危及生命的全身性疾病。hATTR 患者体内会产生突变型和野生型的转甲状蛋白，这些蛋白异常折叠并沉积为淀粉样蛋白，主要累积于周围神经、心脏、肾脏和胃肠道，导致多发性神经病变和心肌病。转甲状蛋白主要由肝脏产生，并以同源四聚体的形式运载视黄醇、甲状腺素和维生素 A。hATTR 患者由于转甲状蛋白异常，会出现维生素 A 缺乏，因此需要每日补充维生素 A。以往，hATTR 的治疗方案主要包括原位肝移植或使用稳定 TTR 四聚体的药物，例如 tafamidis 或 diflunisal。然而，这些传统疗法并不能阻止疾病的进展。</span>

![485053_1_En_5_Fig3_HTML](https://raw.githubusercontent.com/zcgkiller/Pictures/main/Wechat/485053_1_En_5_Fig3_HTML.png)

<span style=font-family:kaiti;text-align:center;>**Fig. 3** Schematic illustration of the secondary structures of patisiran and givosiran. (**a**) Patisiran is an LNP-encapsulated siRNA (ALN-TTR02) targeting transthyretin (TTR) for the treatment of hereditary transthyretin amyloidosis (hATTR). All of the pyrimidines in the sense strand and two of the uridines in the antisense strand of patisiran contain 2′-*O*-Me-modified sugars, and both strands contain 2′-deoxythymidine (dT) dinucleotide overhangs at their 3′-ends. (**b**) Givosiran (ALN-AS1) is a GalNAc-conjugated siRNA drug targeting aminolevulinate synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP). The nucleotides are all chemically modified with either 2′-*O*-Me or 2′-F and the 3′ end of the sense strand is covalently linked to GalNAc to enable specific delivery of the siRNA drug to hepatocytes <span style=color:blue>patisiran 和 givosiran 二级结构示意图。（**a**）Patisiran 是一种 LNP 封装的 siRNA（ALN-TTR02），靶向转甲状腺素蛋白（TTR），用于治疗遗传性转甲状腺素蛋白淀粉样变性（hATTR）。patisiran 的正义链中的所有嘧啶和反义链中的两个尿苷都含有 2′-*O*-Me 修饰的糖，并且两条链在其 3′ 端都含有 2′-脱氧胸苷 (dT) 二核苷酸悬垂。（**b**）Givosiran (ALN-AS1) 是一种 GalNAc 结合的 siRNA 药物，靶向氨基乙酰丙酸合酶 1 (ALAS1)，用于治疗急性肝卟啉症 (AHP)。所有核苷酸均经过 2′-*O*-Me 或 2′-F 化学修饰，正义链的 3′ 端与 GalNAc 共价连接，从而能够将 siRNA 药物特异性递送至肝细胞</span></span>

Patisiran targets a conserved sequence in the 3′ untranslated region of both mutant and wild-type TTR mRNA, leading to its degradation and a 86.8% reduction in serum TTR protein levels and tissue TTR deposits primarily in the liver. Patisiran (ALN-TTR02) is formulated as a 100 nm LNP composed of the siRNA (ALN-18328) and four lipid components of which two are constituents of other approved drugs (DSPC [1,2-distearoyl-*sn*-glycero-3-phosphocholine] and cholesterol), and two novel lipid components (DLin-MC3-DMA [(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate] and PEG2000-C-DMG [α-(3′-{[1,2-di(myristyloxy)proponoxy] carbonylamino}propyl)-ω-methozy,polyoxyethylene]). All of the pyrimidines in the sense strand and two of the uridines in the antisense strand of patisiran contain 2′-*O*-methyl modified sugars with the remaining being unmodified ribonucleotides. Both guide and passenger strands contain 2′-deoxythymidine dinucleotide overhangs at their respective 3′-ends. All internucleotide linkages are natural, unmodified phosphodiester linkages (Fig. 3a).

<span style=color:blue>Patisiran (ALN-TTR02) 靶向转甲状蛋白 (TTR) mRNA 3' 非翻译区 (UTR) 的保守序列，导致其降解，从而使血清 TTR 蛋白水平降低 86.8%，并主要降低肝脏组织中的 TTR 沉积。Patisiran是一种由 100 nm 的脂质纳米颗粒 (LNP) 递送的 siRNA 药物。该 LNP 由 siRNA (ALN-18328) 和四种脂质成分组成，其中两种为其他获批药物的成分 (DSPC [1,2-distearoyl-sn-glycero-3-磷酸胆碱] 和胆固醇)，另外两种为新型脂质成分 (DLin-MC3-DMA [(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate] 和 PEG2000-C-DMG [α-(3′-{[1,2-di(myristyloxy)proponoxy] carbonylamino}propyl)-ω-methoxy,polyoxyethylene])。Patisiran 的正义链中的所有嘧啶核苷和反义链中的两个尿苷都含有2′-O-甲基修饰的糖基，其余为未修饰的核糖核苷酸。引导链和乘客链在各自的3′端含有2′-脱氧胸腺苷二核苷酸悬垂。所有核苷酸之间的磷酸二酯键均为自然未修饰的磷酸二酯键（见图3a）。</span>

The chemical design of patisiran protects the siRNA and allows passive uptake into hepatocytes upon systemic delivery by i.v. infusion at a dose of 0.3 mg/kg every 3 weeks. Disease progression was halted or reversed with patisiran treatment, which included a transition from assisted to unassisted walking. More importantly, cardiac manifestations of hATTR were also improved. The adverse effects are mostly mild and infusion-related. However, seven patients (5%) in the patisiran group died compared to six patients (8%) in the placebo group in phase III clinical trial. The causes of death were primarily cardiovascular in nature and consistent with those expected in patients with hATTR.

<span style=color:blue>Patisiran的化学设计能够保护 siRNA，并允许其在通过静脉输注 (i.v.) 以 0.3 mg/kg 的剂量进行全身递送后被动地被肝细胞摄取。帕替沙兰治疗可阻断或逆转疾病进展，例如一位患者能够从使用辅助行走工具转变为无需辅助即可行走。更重要的是，hATTR 的心脏症状也得到改善。帕替沙兰治疗耐受性良好，不良反应大多轻微且与输注相关。然而，在 III 期临床试验中，帕替沙兰组有 7 名患者 (5%) 死亡，安慰剂组有 6 名患者 (8%) 死亡。死亡原因主要为心血管方面的原因，与 hATTR 患者的预期情况一致。</span>

Givosiran is a GalNAc-conjugated siRNA drug targeting aminolevulinate synthase 1 (ALAS1) for the treatment of AHP. AHP comprises four genetic disorders each caused by distinct enzyme defects in the heme biosynthesis pathway in the liver, leading to abnormal accumulation of toxic heme precursors, such as δ-aminolevulinic acid (ALA) and porphobilinogen (PBG). This causes acute porphyria attacks that primarily manifest as neurovisceral symptoms such as abdominal pain (cardinal symptom), acute neuropathy, and psychiatric symptoms, such as hallucinations, anxiety and paranoia. Most symptomatic patients have few attacks in their lifetime; however, up to 5% of patients will have recurrent attacks (≥4 attacks per year). The estimated prevalence of AHP is 5.4 per million individuals.

<span style=color:blue>Givosiran是一种靶向 δ-氨基乙酰丙酸合酶 1 (ALAS1) 的 GalNAc 缀合 siRNA 药物，用于治疗急性肝卟啉病 (AHP)。AHP 包括四种遗传性疾病，每种疾病均由肝脏血红素生物合成途径中不同酶缺陷引起，导致毒性血红素前体物质 (例如 δ-氨基乙酰丙酸 (ALA) 和尿卟啉原 (PBG)) 异常积累。这会导致急性卟啉症发作，主要表现为神经内脏症状，例如腹痛 (主要症状)、急性神经病变以及精神症状 (如幻觉、焦虑和偏执妄想)。大多数有症状的患者一生中发病次数较少；然而，多达 5% 的患者会出现复发性发作 (每年 ≥ 4 次发作)。AHP 的估计患病率为百万分之一 5.4。</span>

Givosiran is chemically modified with PS backbone linkages, and 2′-OMe and 2′-F sugars, and covalently linked to GalNAc to enable specific delivery of the siRNA drug to hepatocytes (Fig. 3b). This results in knockdown of the liver-expressed ALAS1 mRNA preventing accumulation of neurotoxic ALA and PBG levels that are associated with acute porphyria attacks. Clinical phase III study showed that administration of givosiran by s.c. injections at 2.5 mg/kg once monthly results in dose-dependent knockdown of ALAS1 mRNA (up to 86% knockdown), 91% reduction of the ALA protein and 96% reduction in PBG in the liver, urine, and serum samples. These reductions prevent ALA formation, decrease 5-ALA levels and prevent the production of porphyrins and hemes, such as PBG. After a 6-month treatment, mean ALA and PBG levels were reduced from baseline by 77% and 76%, respectively, and more importantly, the median annual attack rate was significantly decreased by 90% in the givosiran treatment group. In November 2019, givosiran was approved by the FDA for the treatment of adults with AHP based on the positive results from the multinational, phase III ENVISION trial. In the EU, givosiran received a positive opinion in January 2020 for the treatment of AHP in adults and adolescents aged 12 years and older.

<span style=color:blue>Givosiran经过化学修饰，具有磷硫酸 (PS) 骨架键，2'-OMe 和 2'-F 糖基，并通过共价键连接 GalNAc 糖基，使 siRNA 药物能够特异性地递送至肝细胞 (图 3b)。这导致肝脏表达的 ALAS1 mRNA 被敲低，从而阻止神经毒性 ALA 和 PBG 水平的积累，这些代谢物与急性卟啉症发作有关。临床 III 期研究表明，每月一次皮下注射 2.5 mg/kg 的Givosiran剂量可使 ALAS1 mRNA 剂量依赖性敲低 (最高可达 86%)，肝脏、尿液和血清样本中 ALA 蛋白减少 91%，PBG 减少 96%。这些降低阻止了 ALA 的形成，降低了 5-ALA 水平，并阻止了卟啉和血红素 (例如 PBG) 的产生。经过 6 个月的治疗，平均 ALA 和 PBG 水平分别较基线降低了 77% 和 76%。更重要的是，Givosiran治疗组的年发病率中位数下降了 90%。2019 年 11 月，基于来自多国 III 期 ENVISION 试验的阳性结果，吉沃西兰被 FDA 批准用于治疗成人 AHP。2020 年 1 月，欧盟批准吉沃西兰用于治疗 12 岁及以上青少年和成人 AHP。</span>

## 6 Concluding Remarks and Future Perspectives 总结与展望

Since the discovery of the RNAi pathway in 1998, siRNAs have become a powerful tool for studying gene function and for the development of RNA-targeted therapeutics. Importantly, siRNA-based drugs have several advantages compared to small molecules and monoclonal antibody drugs, which include efficient knockdown of previously undruggable targets, rapid lead optimization, and readily scalable drug manufacturing process. Such features have attracted many researchers and pharmaceutical companies to develop siRNA-based therapeutics. With the emergence of new chemical modifications and improved targeting technologies, the field of RNA therapeutics is experiencing a renaissance. The clinically validated LNPs, GalNAc conjugates, and DPC delivery platforms will continue to produce many new siRNA drugs for the treatment of liver diseases, while ongoing research into new delivery strategies is focusing on effective delivery beyond the liver. Reaching the central and peripheral nervous systems (CNS, PNS), respectively, is highly important, due to the unmet medical need for several neurological pathologies. Indeed, recent efforts have shifted toward delivery to the CNS, where strategies to cross the blood-brain barrier include receptor-mediated delivery and intrathecal injections. For example, single well-tolerated intrathecal injections of an siRNA-conjugate in rodent and nonhuman primate models resulted in robust gene silencing throughout the whole CNS, as reported by Alnylam. Other specific administration routes such as intravitreal injection, intratracheal administration, and aerosol inhalation are also being developed for treating ocular and respiratory disorders, respectively. The recent regulatory approvals of ONPATTRO™ (patisiran) and GIVLLARI™ (givosiran) are success stories that will pave the way for the development of new siRNA drugs for the treatment of a wide array of diseases in the coming years.

<span style=color:blue>自从 1998 年发现 RNAi 机制以来，siRNA 已经成为研究基因功能和开发 RNA 靶向治疗药物的重要工具。与小分子药物和单克隆抗体药物相比，siRNA 疗法具有诸多优势，例如能够高效抑制传统药物难以靶向的基因、快速优化先导化合物以及简便易于规模化的药物生产工艺。这些特点吸引了众多研究人员和制药公司投入到 siRNA 药物的研发之中。随着新型化学修饰方法和靶向技术不断涌现，RNA 疗法领域正经历着复兴。经过临床验证的脂质纳米颗粒 (LNP)、GalNAc 缀合物和 DPC 递送平台将继续催生大量用于治疗肝脏疾病的 siRNA 药物，同时，针对肝脏以外靶器官的递送策略也正在积极研究中。有效递送至中枢神经系统 (CNS) 和周围神经系统 (PNS) 对于治疗一系列神经系统疾病具有重要意义，因为这些疾病目前尚缺乏有效的治疗手段。近年来，研究人员将注意力转向了如何递送 siRNA 至中枢神经系统，相关策略包括受体介导递送和鞘内注射。例如，Alnylam 公司报道了在啮齿动物和非人类灵长类模型中，单次鞘内注射 siRNA 缀合物即可在整个中枢神经系统实现有效的基因沉默，且具有良好的耐受性。此外，针对眼部和呼吸系统疾病，其他特异性给药途径例如玻璃体腔内注射、气管内给药和雾化吸入等方法也在被开发之中。像 ONPATTRO™ (patisiran) 和 GIVLAARI™ (patisiran) 等 siRNA 药物的获批上市，是该领域的成功案例，并将为未来几年开发治疗各种疾病的新型 siRNA 药物铺平道路。</span>